



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: December 28, 2004 Signature:

Shawn P. Foley
(Shawn P. Foley)

Docket No.:
FELDER 3.9-001 CONT DIV
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Felder et al.

Application No.: 10/677,983

Group Art Unit: 1645

Filed: October 2, 2003

Examiner: Not Yet Assigned

For: G PROTEIN-RELATED KINASE MUTANTS
IN ESSENTIAL HYPERTENSION

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:


It is respectfully requested that the references listed on the enclosed form be made of record and considered with respect to the above-referenced U.S. patent application. A copy of each reference was of record in Application No. 09/614,748, the benefit of which is claimed under §120. Submission of the present Information Disclosure Statement should not be taken as an admission that the cited references are legally available prior art or that the same are pertinent or material.

In the event that any fee is due in connection with the present Information Disclosure Statement, the Commissioner is hereby authorized to charge the same to our Deposit Account No. 12-1095.

Dated: December 28, 2004

Respectfully submitted,

By *Shawn P. Foley*
Shawn P. Foley
Registration No.: 33,071
LERNER, DAVID, LITTENBERG,
KRUMHOLZ & MENTLIK, LLP
600 South Avenue West
Westfield, New Jersey 07090
(908) 654-5000
Attorney for Applicant



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/677,983
				Filing Date	October 2, 2003
				First Named Inventor	Robin A. Felder
				Art Unit	1645
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	FELDER 3.9-001 CONT DIV

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)					

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Elseth et al. Principles of Modern Genetics pp. 542-545 1994.	
	CB	Casari et al. Hypertension 25(3):320-326 (1995).	
	CC	Virlon et al. Endocrinology 139(5):2784-2795 (1998).	
	CD	Courjault-Gautier et al., J. Am. Soc. Nephrol. 5:1949-1963 (1994).	
	CE	Detrisac, et al., Kidney Int. 25:383-390 (1984).	
	CF	Jose et al., Pharmacol Ther 80:149-182 (1998).	
	CG	Ng et al., Eur. J. Pharmacol. 267:7-19 (1994).	
	CH	Premont, et al., FASEB J. 9:175-182 (1995).	
	CI	Palczewski, Protein Sci. 3:1355-1361 (1994).	
	CJ	Inglese, et al., J. Biol. Chem. 268:23735-23738 (1993).	
	CK	Gros, J. Clin. Invest. 99(9):2087-2093 (1997).	
	CL	Ambrose, et al., Hum. Mol. Genet. 1:697-703 (1993).	
	CM	Sallese et al., Biochem. Biophys. Res. Commun. 199:848-854 (1994).	
	CN	Menard, et al., Biochemistry 35(13):4155-4160 (1996).	
	CO	Loudon, et al., J. Biol. Chem. 272(43):27422-27427 (1997).	
	CP	Premont, et al., J. Biol. Chem. 271(11):6403-6410 (1996).	
	CQ	Albrecht, et al., J. Clin. Invest. 97(10):2283-2288 (1996).	
	CR	Ohbu, et al., American J. of Physiology 268:R231-R235 (1995).	
	CS	Eisner, et al., Am. J. Physiol. 273:R317-R323 (1997).	
	CT	Jin, et al., Am. J. Physiol. 273:C1623-C1631 (1997).	
	CU	Woost, et al., Kidney International 50:125-134 (1996).	
	CV	Chen, et al., Kidney International 49:153-157 (1996).	
	CW	Racusen, et al., Kidney International 48:536-543 (1995).	
	CX	Ryan, et al., Kidney International 45:48-57 (1994).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
529961_1.DOC

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--